It looks like a key Valeant deal might be falling apart, and now the stock is tanking

Valeant’s stock is tanking after Dow Jones reported that talks to sell its Salix unit to Takeda have broken down.

Valeant’s stock fell as much as 6% this morning.

The embattled pharma company had been in talks to sell the unit to Japan’s Takeda for $10 billion.

The stock jumped up the stock 30% on the news.

This is a developing story. More to follow.

NOW WATCH: Richard Branson: Entrepreneurs need to fill the gap where government is lacking

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.